Services

IgA-Albumin Binding Domain (Abd) Fusion Protein Production Service

Background Service Advantages Applications FAQs

Prolonging IgA Persistence through Albumin-Directed FcRn Recycling

One of the primary limitations of IgA antibodies as therapeutic candidates is their inherently short half-life in circulation. At Creative Biolabs, we provide a dedicated IgA-Albumin Binding Domain (Abd) Fusion Protein Production Service that enables indirect FcRn pathway engagement by leveraging the natural recycling mechanism of serum albumin.

By fusing albumin-binding domains (Abd) to IgA molecules, we facilitate interactions with circulating albumin, which in turn interacts with the neonatal Fc receptor (FcRn). This strategy offers a robust solution for enhancing the stability and persistence of IgA constructs in systemic environments—while preserving their native effector functions and mucosal immunity.

Service Highlights

Modular Abd Fusion Design

We design flexible fusion constructs by integrating well-characterized albumin-binding domains (such as ABD035 or engineered variants) at either N- or C-terminal ends of the IgA molecule.
Linker regions are customized to optimize spatial orientation, structural flexibility, and receptor accessibility while avoiding disruption of antigen-binding regions.

Expression Optimization for IgA-Abd Fusion Constructs

Constructs are expressed in mammalian systems (CHO or HEK293), ensuring accurate glycosylation and native folding of the IgA backbone.
We support both monomeric and dimeric forms of IgA1 or IgA2, and scalable expression from microgram to multi-milligram levels.

Integrated Affinity & Biophysical Analysis

Binding to human and cross-species albumin is assessed using SPR, ELISA, and pull-down assays under different pH conditions.
Additional tests include thermal stability (Tm), size homogeneity (SEC-HPLC), and aggregation propensity (DLS) to ensure manufacturability.

Functional Validation of IgA Activity

Post-fusion, we validate that the FcαRI interaction and antigen specificity are fully retained.
Optional testing includes epitope recognition, polymeric assembly, and FcRn-mediated recycling modeling via albumin engagement.

Advantages of Our Service

Non-invasive Half-Life Extension: Leverages the native FcRn-albumin recycling pathway without modifying the IgA Fc directly.
Broad Species Compatibility: ABDs often retain cross-species albumin binding, enabling use in multiple model systems.
Maintained IgA Functionality: Fusion design preserves key IgA functions such as FcαRI engagement, mucosal transport, and polymeric structure.
Modular and Scalable: Suitable for quick screening or larger-scale research production.

Applications

Fig.1 Applications of this service. (Creative Biolabs Original)

FAQs

Q1: What is the rationale for using albumin binding instead of directly engineering IgA-Fc?

A1: Albumin binding offers a non-disruptive strategy to exploit the FcRn pathway. It avoids direct Fc modifications, thus preserving native IgA glycosylation and effector functions.

Q2: Can I choose a specific albumin-binding domain?

A2: Yes. We offer a panel of ABD variants with different affinities and species reactivity, and can custom-design according to your specifications.

Q3: Will the fusion interfere with antigen recognition?

A3: No. We optimize linker length and fusion site to prevent structural hindrance and validate antigen-binding activity post-expression.

Q4: Do you provide small-scale and mid-scale expression options?

A4: Yes. We support flexible scale expression to accommodate early-stage development, functional screening, or preclinical validation.

For research use only. Not intended for any clinical use.

Send Inquiry

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.